#eli lilly and company

[thepastisalreadywritten]

[ofstoriesnotatoms]

"Insulin does not belong to me, it belongs to the world."

- Frederick G. Banting (Canadian recipient of the Nobel Prize in Physiology and Medicine for co-discovering insulin who sold the insulin patent for a mere $1)

[sidewalkchemistry]

[donnieisaprettyboy]

keep in mind if you go to a pride parade it is going to be FULL of companies and politicians attempting to advertise to you in a rainbow cape. the pride parade I went to had people from pharmaceutical and drug companies and I’m pretty sure a company that makes engines for war machinery. DONT be fooled by this.

there’s plenty of great, local queer communities that make pride beautiful and enjoyable. the advertising is unavoidable, but please don’t be tricked into thinking these are the “good companies” or that they’re “exceptions.” they do horrible shit and just put on a rainbow every June.

[they-breasted-boobily]

14) the two days when twitter verification had absolutely no restrictions

the best days to have been on the internet:

1) nov 5th 2020

2) the day the queen croaked

3) april 1st 2013 (mishapocalypse)

4) april 1st 2024 (boop)

5) when the evergiven got stuck in suez canal

6) when trump got covid

7) four seasons landscaping

8) jan 6th insurrection

9) skeleton war

10) dashcon

11) bisexual firefighter

12) battle of the joshes

13) dec 21st 2012

[peptide-ltd]

Retatrutide, the Latest Weight Loss Peptidein 2023

Introduction

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is set for FDA approval. Retatrutide is in the same class as other weight loss drugs like Semaglutide and Tirzepatide. However, what sets it apart from other obesity medications is that it targets three hunger-reducing hormones. Semaglutide only targets one hunger-controlling hormone called GLP-1, while Tirzepatide targets GLP-1 and GIP. Retatrutide takes it a notch higher by targeting three hunger-regulating hormones: GIP, GLP-1, and glucagon receptor.

If single or dual receptor agonist drugs are already effective, this triple-agonist, or triagonist, new molecular entity promises to deliver even greater results. That will be very helpful for individuals struggling with obesity or, for example, those who are not losing weight on Semaglutide and Tirzepatide. Since Retatrutide hasn’t available from Eli Lilly, If you want to start your own research on Retatrutide peptide, please make sure to buy it from a reputable Retatrutide powder supplier. Buy Retatrutide powder bulk will get a good price.

Retatrutide weight loss facts

Phase II trial

In recent results from its Phase II trial (NCT04881760), data showed that after 48 weeks, in the retatrutide dosage 1mg, 4mg, 8mg, and 12mg groups, -8.7%, -17.1%, -22.8%, and -24.2% percentage change in body weight was recorded. Furthermore, a weight reduction of 15% or more was recorded in 60% of subjects in the study. With regards to safety, the most common adverse events were of a gastrointestinal nature, and thus retatrutide’s safety profile was on par with other incretin-based therapies.

A Phase III trial (TRIUMPH-3; NCT05882045) began in May, studying the effects of retatrutide in patients with severe obesity and established cardiovascular disease, and is estimated to end in November 2025.

Benefits of Retatrutide--Retatrutide vs Tirzepatide vs Semalgutide

Again, research into retatrutide peptide is ongoing. But data so far show that retatrutide may help people lose even more weight than other Tirzepatide and Semaglutide. According to previous research on people, here are some of the clinical trials results:

Novo Nordisk’s semaglutide was found to reduce body weight, on average, by around 15%, or about 34 pounds, after 68 weeks.

And Lilly’s other weight loss drug, tirzepatide, was shown to reduce body weight, by 22.5% on average, or about 52 pounds, after 72 weeks.

The experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds,after 48 weeks. However, this is a limited-time effect, and the actual Retatrutide benefits could be even better. Phase three trials would reveal the full potential and long-term effects, making it easy for people to trust it.

To be sure, these are not direct comparisons because the drugs were not compared in a head-to-head clinical trial. What benefits we can expect from Retatrutide powder are weight loss and type 2 diabetes treatment. But Retatrutide has the potential to work faster and more effectively than Tirzepatide and Semaglutide.

[mostlysignssomeportents]

What the fuck is a PBM?

TOMORROW (Sept 24), I'll be speaking IN PERSON at the BOSTON PUBLIC LIBRARY!

Terminal-stage capitalism owes its long senescence to its many defensive mechanisms, and it's only by defeating these that we can put it out of its misery. "The Shield of Boringness" is one of the necrocapitalist's most effective defenses, so it behooves us to attack it head-on.

The Shield of Boringness is Dana Claire's extremely useful term for anything so dull that you simply can't hold any conception of it in your mind for any length of time. In the finance sector, they call this "MEGO," which stands for "My Eyes Glaze Over," a term of art for financial arrangements made so performatively complex that only the most exquisitely melted brain-geniuses can hope to unravel their spaghetti logic. The rest of us are meant to simply heft those thick, dense prospectuses in two hands, shrug, and assume, "a pile of shit this big must have a pony under it."

MEGO and its Shield of Boringness are key to all of terminal-stage capitalism's stupidest scams. Cloaking obvious swindles in a lot of complex language and Byzantine payment schemes can make them seem respectable just long enough for the scammers to relieve you of all your inconvenient cash and assets, though, eventually, you're bound to notice that something is missing.

If you spent the years leading up to the Great Financial Crisis baffled by "CDOs," "synthetic CDOs," "ARMs" and other swindler nonsense, you experienced the Shield of Boringness. If you bet your house and/or your retirement savings on these things, you experienced MEGO. If, after the bubble popped, you finally came to understand that these "exotic financial instruments" were just scams, you experienced Stein's Law ("anything that can't go forever eventually stops"). If today you no longer remember what a CDO is, you are once again experiencing the Shield of Boringness.

As bad as 2008 was, it wasn't even close to the end of terminal stage capitalism. The market has soldiered on, with complex swindles like carbon offset trading, metaverse, cryptocurrency, financialized solar installation, and (of course) AI. In addition to these new swindles, we're still playing the hits, finding new ways to make the worst scams of the 2000s even worse.

That brings me to the American health industry, and the absurdly complex, ridiculously corrupt Pharmacy Benefit Managers (PBMs), a pathology that has only metastasized since 2008.

On at least 20 separate occasions, I have taken it upon myself to figure out how the PBM swindle works, and nevertheless, every time they come up, I have to go back and figure it out again, because PBMs have the most powerful Shield of Boringness out of the whole Monster Manual of terminal-stage capitalism's trash mobs.

PBMs are back in the news because the FTC is now suing the largest of these for their role in ripping off diabetics with sky-high insulin prices. This has kicked off a fresh round of "what the fuck is a PBM, anyway?" explainers of extremely variable quality. Unsurprisingly, the best of these comes from Matt Stoller:

https://www.thebignewsletter.com/p/monopoly-round-up-lina-khan-pharma

Stoller starts by pointing out that Americans have a proud tradition of getting phucked by pharma companies. As far back as the 1950s, Tennessee Senator Estes Kefauver was holding hearings on the scams that pharma companies were using to ensure that Americans paid more for their pills than virtually anyone else in the world.

But since the 2010s, Americans have found themselves paying eye-popping, sky-high, ridiculous drug prices. Eli Lilly's Humolog insulin sold for $21 in 1999; by 2017, the price was $274 – a 1,200% increase! This isn't your grampa's price gouging!

Where do these absurd prices come from? The story starts in the 2000s, when the GW Bush administration encouraged health insurers to create "high deductible" plans, where patients were expected to pay out of pocket for receiving care, until they hit a multi-thousand-dollar threshold, and then their insurance would kick in. Along with "co-pays" and other junk fees, these deductibles were called "cost sharing," and they were sold as a way to prevent the "abuse" of the health care system.

The economists who crafted terminal-stage capitalism's intellectual rationalizations claimed the reason Americans paid so much more for health care than their socialized-medicine using cousins in the rest of the world had nothing to do with the fact that America treats health as a source of profits, while the rest of the world treats health as a human right.

No, the actual root of America's health industry's problems was the moral defects of Americans. Because insured Americans could just go see the doctor whenever they felt like it, they had no incentive to minimize their use of the system. Any time one of these unhinged hypochondriacs got a little sniffle, they could treat themselves to a doctor's visit, enjoying those waiting-room magazines and the pleasure of arranging a sick day with HR, without bearing any of the true costs:

https://pluralistic.net/2021/06/27/the-doctrine-of-moral-hazard/

"Cost sharing" was supposed to create "skin in the game" for every insured American, creating a little pain-point that stung you every time you thought about treating yourself to a luxurious doctor's visit. Now, these payments bit hardest on the poorest workers, because if you're making minimum wage, at $10 co-pay hurts a lot more than it does if you're making six figures. What's more, VPs and the C-suite were offered "gold-plated" plans with low/no deductibles or co-pays, because executives understand the value of a dollar in the way that mere working slobs can't ever hope to comprehend. They can be trusted to only use the doctor when it's truly warranted.

So now you have these high-deductible plans creeping into every workplace. Then along comes Obama and the Affordable Care Act, a compromise that maintains health care as a for-profit enterprise (still not a human right!) but seeks to create universal coverage by requiring every American to buy a plan, requiring insurers to offer plans to every American, and uses public money to subsidize the for-profit health industry to glue it together.

Predictably, the cheapest insurance offered on the Obamacare exchanges – and ultimately, by employers – had sky-high deductibles and co-pays. That way, insurers could pocket a fat public subsidy, offer an "insurance" plan that was cheap enough for even the most marginally employed people to afford, but still offer no coverage until their customers had spent thousands of dollars out-of-pocket in a given year.

That's the background: GWB created high-deductible plans, Obama supercharged them. Keep that in your mind as we go through the MEGO procedures of the PBM sector.

Your insurer has a list of drugs they'll cover, called the "formulary." The formulary also specifies how much the insurance company is willing to pay your pharmacist for these drugs. Creating the formulary and paying pharmacies for dispensing drugs is a lot of tedious work, and insurance outsources this to third parties, called – wait for it – Pharmacy Benefits Managers.

The prices in the formulary the PBM prepares for your insurance company are called the "list prices." These are meant to represent the "sticker price" of the drug, what a pharmacist would charge you if you wandered in off the street with no insurance, but somehow in possession of a valid prescription.

But, as Stoller writes, these "list prices" aren't actually ever charged to anyone. The list price is like the "full price" on the pricetags at a discount furniture place where everything is always "on sale" at 50% off – and whose semi-disposable sofas and balsa-wood dining room chairs are never actually sold at full price.

One theoretical advantage of a PBM is that it can get lower prices because it bargains for all the people in a given insurer's plan. If you're the pharma giant Sanofi and you want your Lantus insulin to be available to any of the people who must use OptumRX's formulary, you have to convince OptumRX to include you in that formulary.

OptumRX – like all PBMs – demands "rebates" from pharma companies if they want to be included in the formulary. On its face, this is similar to the practices of, say, NICE – the UK agency that bargains for medicine on behalf of the NHS, which also bargains with pharma companies for access to everyone in the UK and gets very good deals as a result.

But OptumRX doesn't bargain for a lower list price. They bargain for a bigger rebate. That means that the "price" is still very high, but OptumRX ends up paying a tiny fraction of it, thanks to that rebate. In the OptumRX formulary, Lantus insulin lists for $403. But Sanofi, who make Lantus, rebate $339 of that to OptumRX, leaving just $64 for Lantus.

Here's where the scam hits. Your insurer charges you a deductible based on the list price – $404 – not on the $64 that OptumRX actually pays for your insulin. If you're in a high-deductible plan and you haven't met your cap yet, you're going to pay $404 for your insulin, even though the actual price for it is $64.

Now, you'd think that your insurer would put a stop to this. They chose the PBM, the PBM is ripping off their customers, so it's their job to smack the PBM around and make it cut this shit out. So why would the insurers tolerate this nonsense?

Here's why: the PBMs are divisions of the big health insurance companies. Unitedhealth owns OptumRx; Aetna owns Caremark, and Cigna owns Expressscripts. So it's not the PBM that's ripping you off, it's your own insurance company. They're not just making you pay for drugs that you're supposedly covered for – they're pocketing the deductible you pay for those drugs.

Now, there's one more entity with power over the PBM that you'd hope would step in on your behalf: your boss. After all, your employer is the entity that actually chooses the insurer and negotiates with them on your behalf. Your boss is in the driver's seat; you're just along for the ride.

It would be pretty funny if the answer to this was that the health insurance company bought your employer, too, and so your boss, the PBM and the insurer were all the same guy, busily swapping hats, paying for a call center full of tormented drones who each have three phones on their desks: one labeled "insurer"; the second, "PBM" and the final one "HR."

But no, the insurers haven't bought out the company you work for (yet). Rather, they've bought off your boss – they're sharing kickbacks with your employer for all the deductibles and co-pays you're being suckered into paying. There's so much money (your money) sloshing around in the PBM scamoverse that anytime someone might get in the way of you being ripped off, they just get cut in for a share of the loot.

That is how the PBM scam works: they're fronts for health insurers who exploit the existence of high-deductible plans in order to get huge kickbacks from pharma makers, and massive fees from you. They split the loot with your boss, whose payout goes up when you get screwed harder.

But wait, there's more! After all, Big Pharma isn't some kind of easily pushed-around weakling. They're big. Why don't they push back against these massive rebates? Because they can afford to pay bribes and smaller companies making cheaper drugs can't. Whether it's a little biotech upstart with a cheaper molecule, or a generics maker who's producing drugs at a fraction of the list price, they just don't have the giant cash reserves it takes to buy their way into the PBMs' formularies. Doubtless, the Big Pharma companies would prefer to pay smaller kickbacks, but from Big Pharma's perspective, the optimum amount of bribes extracted by a PBM isn't zero – far from it. For Big Pharma, the optimal number is one cent higher than "the maximum amount of bribes that a smaller company can afford."

The purpose of a system is what it does. The PBM system makes sure that Americans only have access to the most expensive drugs, and that they pay the highest possible prices for them, and this enriches both insurance companies and employers, while protecting the Big Pharma cartel from upstarts.

Which is why the FTC is suing the PBMs for price-fixing. As Stoller points out, they're using their powers under Section 5 of the FTC Act here, which allows them to shut down "unfair methods of competition":

https://pluralistic.net/2023/01/10/the-courage-to-govern/#whos-in-charge

The case will be adjudicated by an administrative law judge, in a process that's much faster than a federal court case. Once the FTC proves that the PBM scam is illegal when applied to insulin, they'll have a much easier time attacking the scam when it comes to every other drug (the insulin scam has just about run its course, with federally mandated $35 insulin coming online, just as a generation of post-insulin diabetes treatments hit the market).

Obviously the PBMs aren't taking this lying down. Cigna/Expressscripts has actually sued the FTC for libel over the market study it conducted, in which the agency described in pitiless, factual detail how Cigna was ripping us all off. The case is being fought by a low-level Reagan-era monster named Rick Rule, whom Stoller characterizes as a guy who "hangs around in bars and picks up lonely multi-national corporations" (!!).

The libel claim is a nonstarter, but it's still wild. It's like one of those movies where they want to show you how bad the cockroaches are, so there's a bit where the exterminator shows up and the roaches form a chorus line and do a kind of Busby Berkeley number:

https://www.46brooklyn.com/news/2024-09-20-the-carlton-report

So here we are: the FTC has set out to euthanize some rentiers, ridding the world of a layer of useless economic middlemen whose sole reason for existing is to make pharmaceuticals as expensive as possible, by colluding with the pharma cartel, the insurance cartel and your boss. This conspiracy exists in plain sight, hidden by the Shield of Boringness. If I've done my job, you now understand how this MEGO scam works – and if you forget all that ten minutes later (as is likely, given the nature of MEGO), that's OK: just remember that this thing is a giant fucking scam, and if you ever need to refresh yourself on the details, you can always re-read this post.

The paperback edition of The Lost Cause, my nationally bestselling, hopeful solarpunk novel is out this month!

If you'd like an essay-formatted version of this post to read or share, here's a link to it on pluralistic.net, my surveillance-free, ad-free, tracker-free blog:

https://pluralistic.net/2024/09/23/shield-of-boringness/#some-men-rob-you-with-a-fountain-pen

Image: Flying Logos (modified) https://commons.wikimedia.org/wiki/File:Over_$1,000,000_dollars_in_USD_$100_bill_stacks.png

CC BY-SA 4.0 https://creativecommons.org/licenses/by-sa/4.0/deed.en

[what-shitfuckery-is-this-ew]

BOYCOTTING FOR PALESTINE

The Official BDS Boycott Targets

Campaigns

Block the boat: End maritime arms transfer to Israel

Ban Apartheid Israel from Sports (FIFA, Olympics)

CAF get off Israel's train: Boycott CAF

Greenwashing Apartheid

Israeli Spyware

Military Embargo

Farming Injustice

Consumer Boycotts - a complete boycott of these brands

Cisco

Axa

Puma

Carrefour

HP

Siemens

Chevron

Intel

Caltex

Israeli produce

Re/max

Ahava

Texaco

Sodastream

Intel

Organic Boycott Targets - boycotts not initiated by BDS but still complete boycott of these brands

Disney

Macdonald's

Dominos

Papa Johns

Burger King

Pizza Hut

Wix

Divestments and exclusion - pressure governments, institutions, investment funds, city councils, etc. to exclude from procurement contracts and investments and to divest from these

Elbit Systems

CAF

Volvo

CAT

Barclays

JCB

HD Hyundai

TKH Security

HikVision

Pressure - boycotts when reasonable alternatives exist, as well as lobbying, peaceful disruptions, and social media pressure.

Google

Amazon

AirBnb

Booking.Com

Expedia

Teva

Here are some companies that strongly support Israel (but are not Boycott targets). There is no ethical consumption under capitalism and boycotting is a political strategy - not a moral one. If you did try to boycott every supporter of Israel you would struggle to survive because every major company supports Israel (as a result of attempting to keep the US economy afloat), that being said, the ones that are being boycotted by masses and not already on the organic boycott list are coloured red.

5 Star Chocolate

7Days

7Up

Apple

Arsenal FC

ALDO

Arket

Axe

Accenture

Ariel

Adidas

ActionIQ

Aquafina

Amika

AccuWeather

Activia

Adobe

Aesop

Azrieli Group

American Eagle

Amway Corp

Axel Springer

American Airlines

American Express

Atlassian

AdeS

Aquarius

Ayataka

Audi

Barqs

Bain & Company

Bayer

Bank Leumi

Bank Hapoalim

BCG (Boston Consulting Group)

Biotherm

Bershka

Bloomberg

BMW

Boeing

Booz Allen Hamilton

Burberry

Bath & Body Works

Bosch

Bristol Myers Squibb

Capri Holdings

Costa

Carita Paris

CareTrust REIT

Caterpillar

Coach

Cappy

Caudalie

CeraVe

Check Point Software Technologies

Cerelac

Chanel

Chapman and Cutler

Channel

Cheerios

Cheetos

Chevron

Chips Ahoy!

Christina Aguilera

Citi Bank

Codral

Cosco

Canada Dry

Citi

Clal Insurance Enterprises

Clean & Clear

Clearblue

Clinique

Champion

Club Social

Coca Cola

Coffee Mate

Colgate

Comcast

Compass

Caesars

Conde Nast

Cooley LLP

Costco

Côte d’Or

Crest

CV Starr

CyberArk Software

Cytokinetics

Crayola

Cra Z Art

Daimler

Dr Pepper

Del Valle

Daim

Doctor Pepper

Dasani

Doritos

Daz

Dior

Dell

Deloitte

Delta Air Lines

Deutsche Bank

Deutsche Telekom

DHL Group

David Off

Disney

DLA Piper

Domestos

Domino’s

Douglas Elliman

Downy

Duane Morris LLP

Dreft Baby Detergent & Laundry Products

Dreyer’s Grand Ice Cream

eBay

Edelman

Eli Lilly

Evian

Empyrean

Ericsson

Endeavor

EPAM Systems

Estee Lauder

Elbit Systems

EY

Forbes

Facebook

Fairlife

Fanta

First International Bank of Israel

Fiverr

Funyuns

Fuze

Fox News

Fritos

Fox Corp

Gatorade

Gamida Cell

GE

Glamglow

General Catalyst

General Motors

Georgia

Gold Peak

Genesys

Goldman Sachs

Grandma’s Cookies

Garnier

Guess

Greenberg Traurig

Guerlain

Givenchy

H&M

Hadiklaim

Huggies

Hanes

HSBC

Head & Shoulders

Hersheys

Herbert Smith Freehills

Hewlett Packard

Hasbro

Hyundai

Henkel

Harel Insurance Investment & Financial Services

Hewlett Packard Enterprise

HubSpot

Huntsman Corp

IBM

Innocent

Insight Partners

Inditex Group

IT Cosmetics

Instacart

Intermedia

Interpublic Group

Instagram

ICL Group

Intuit

Jazwares

Jefferies

John Lewis

JP Morgan Chase

Jaguar

Johnson & Johnson

JPMorgan

Kenon Holdings

Kate Spade

Kirks’

Kinley Water

KKR

KFC

KKW Cosmetics

Kurkure

Keebler

Kolynos

Kaufland

Kevita

Knorr

KPMG

Lemonade

Lidl

Loblaws

Levi Strauss

Louis Vuitton

Life Water

Levi’s

Levi’s Strauss

LinkedIn

Land Rover

L’Oréal

Lego

Levissima

Live Nation Entertainment

Lufthansa

La Roche-Posay

Lipton

Major League Baseball

Manpower Group

Marriott

Marsh McLennan

Maison Francis Kurkdjian

Mastercard

Mattel

Minute Maid

Monster

Monki

Mainz FC

Mellow Yellow

Mountain Dew

Migdal Insurance

Marks & Spencer

Mirinda

McDermott Will & Emery

Motorola

McKinsey

Merck

Michael Kors

Mizrahi Tefahot Bank

Merck KGaA

Micheal Kors

Milkybar

Maybelline

Mount Franklin

Meta

MeUndies

Mattle

Microsoft

Munchies

Miranda

Morgan Lewis

Moroccanoil

Morgan Stanley

MRC

Nasdaq

Naughty Dog

Nivea

Next

NOS

Nabisco

Nutter Butter

No Frills

National Basketball Association

National Geographic

Nintendo

New Balance

Nutella

Newtons

NVIDIA

Netflix

Nescafe

Nestle

Nesquick

Nike

Nussbeisser

Oreo

Oral B

Old spice

Oysho

Omeprazole

Oceanspray

Opodo

P&G (Procter and Gamble)

Pampers

Pull & Bear

Pepsi

Pfizer

Popeyes

Parker Pens

Philadelphia Cream Cheese

Pizza Hut

Powerade

Purina

Phoenix Holdings

Propel

Ponds

Pure Leaf Green Tea

Power Action Wipes

PwC

Prada

Perry Ellis

Prada Eyewear

Pringles

Payoneer

Procter & Gamble

Purelife

Pureology

Quaker Oats

Reddit

Royal Bank of Canada

Ruffles

Revlon

Ralph Lauren

Ritz

Rolls Royce

Royal

S.Pellegrino

Sabra Hummus

Sabre

Sony

SAP

Simply

Smart Water

Sprite

Schwabe

Shell

Soda Stream

Siemens

StreamElements

Schweppes

Sunsilk

Signal

Skittles

Smart Food

Sobe

Smarties

Sephora

Sam’s Club

Superbus

Samsung

Sodastream

Sunkist

Scotiabank

Sour Patch Kids

Starbucks

Sadaf

Stride

Subway

Tang

Tate’s Bake Shop

The Body Shop

Tesco

Twitch

The Ordinary

Tim Hortons

Tostitos

Timberland

Topo Chico

Tapestry

Tropicana

Tommy Hilfiger

Tommy Hilfiger Toiletries

Turbos

Tom Ford

Taco Bell

Triscuit

TUC

Twix

Tottenham Hotspurs

Twisties

Tripadvisor

Uber

Uber Eats

Urban Decay

Upfield

Unilever

Vicks

Victoria’s Secret

V8

Vaseline

Vitaminwater

Volkswagen

Volvo

Walmart

Wegmans

WhatsApp

Waitrose

Woolworths

Wheat Thins

Walkers

Warner Brothers

Warner Chilcot

Warner Music

Wells Fargo

Winston & Strawn

WingStreet

Wissotzky Tea

WWE

Wheel Washing Powder

Wrigley Company

YouTube

Yvel

Yum Brands

Ziyad

Zara

Zim Shipping

Ziff Davis

[theonion]

INDIANAPOLIS—Announcing that landmark new laboratory methods had made the once dreamed-of medication a reality, pharmaceutical company Eli Lilly unveiled insulin Wednesday that doesn’t work on poor people. “Thanks to our proprietary advancements in cellular technology, the active ingredients in insulin will now only work if the patient makes at least six figures per year,” said Eli Lilly CEO David Ricks, describing how the firm’s pharmacologists had engineered the amino sequence in the insulin molecule to detect whether or not the person taking it had rich blood.

Full story.

[lostjudgmnt]

ELI LILLY COMPANY REDUCING INSULIN PRICES BY 70% AND PUTTING A $35 CAP ON MONTHY OUT OF POCKET PAYMENTS!!!!!!!! EVERYONE CELEBRATE WITH ME THIS IS INCREDIBLE

[mariacallous]

"I’m going to let him go wild on health,” former president Donald Trump said of Robert F. Kennedy Jr. at his Madison Square Garden rally in New York City this past weekend. “I’m going to let him go wild on the food. I’m going to let him go wild on the medicines.”

Kennedy, a former Democrat, suspended his presidential campaign in August and endorsed Trump. He has since launched the Make America Healthy Again campaign, an initiative focused on tackling chronic diseases that Trump has seemingly embraced in recent weeks. Given Kennedy’s anti-vaccination stance and conspiratorial leanings, some policy experts and former government officials are concerned about how his views could shape the nation’s health agenda.

Kennedy has long made false statements about the safety of vaccines and has touted disproven treatments for Covid-19, including ivermectin and hydroxychloroquine. On the campaign trail, he has railed against seed oils, blaming several chronic health conditions on their presence in processed foods.

How much influence Kennedy could have on national health policy will all depend on his role within a future Trump administration. Trump did not clarify his remarks at Sunday’s event, including what position he is considering Kennedy for. According to a CNN report that ran late Tuesday, Kennedy said Trump “promised him control of the public health agencies,” but in an email to WIRED on Wednesday, Steven Cheung, Trump’s campaign communications director, said that formal discussions of who will serve in a second Trump administration are premature.

Trump could be considering Kennedy to lead the Department of Health and Human Services, which has 80,000 federal employees, or one of the agencies within it, such as the Food and Drug Administration or the Centers for Disease Control and Prevention. It would be a departure from his previous top health picks, who had lengthy government or public health careers. For instance, Alex Azar, Trump’s HHS secretary, was deputy HHS secretary under George W. Bush and an executive at drugmaker Eli Lilly. Scott Gottlieb, a physician and investor appointed as FDA commissioner under Trump, had previously worked for the FDA and had served on the boards of pharma and biotech companies.

When asked to elaborate on Kennedy’s health priorities, Amaryllis Fox Kennedy, the former candidate’s campaign director and daughter-in-law, told WIRED: “Bobby aims to end conflicts and corruption at the agencies, ensure all testing is undertaken by scientists who have no financial interest in the outcome, and all results of all trials are released to the public. The free market will take care of it from there.” (The National Institutes of Health already requires results of clinical trials funded by the agency to be published to a government database.)

Jerome Adams, US surgeon general under Trump and current executive director of health equity initiatives at Purdue University, says that even if Kennedy were tapped to lead HHS, the FDA, or the CDC, it’s unlikely that he would ascend to one of those roles due to his lack of medical training and controversial views on public health issues. “Congressional approval is required for these positions, and his stances could be a barrier,” Adams says.

If Republicans control the Senate after next week’s election, though, that calculus could change. “The GOP has generally fallen into line in terms of supporting candidates that President Trump does,” says Genevieve Kanter, associate professor of public policy at the University of Southern California.

If chosen to be FDA commissioner, Kennedy would control the agency’s budget and priorities and could have a sizable impact by installing lower-level appointees who are sympathetic to his worldview. While the FDA commissioner does not single-handedly approve or authorize new drugs, Kantner says outside political pressure can certainly influence that process. Kennedy could also appoint members to FDA advisory committees, panels of outside experts that make recommendations to the agency on drug approvals and other regulatory matters. The FDA often follows the recommendations of advisory committees when making decisions on new drug approvals, but not always.

The FDA can also choose to not enforce some rules in certain circumstances—what’s known as enforcement discretion. Given his support for dubious and unproven therapies, such as stem cells and hyperbaric oxygen, an FDA under Kennedy, for instance, could choose to not go after companies that market unapproved treatments.

“When we think of the kind of person we want to be head of HHS or be FDA commissioner, someone ‘going wild’ isn’t exactly the first trait that comes to mind,” Kanter says. “It wouldn’t ease the public’s concern that we would see more food safety incidents and adverse events from poorly regulated drugs and devices from a lax administration that is known for embracing unscientific theories.”

Kennedy wouldn’t have free rein though. Existing laws and regulations govern how the agency works, and a new FDA commissioner wouldn’t be able to get rid of those quickly. “If you’re dealing with regulatory issues that have been long-standing and have lots of precedent, it’s just not possible to turn some of those things around or dismiss them overnight,” says a past leader of the FDA, who requested anonymity so that they could speak freely.

Likewise, even in a leadership role at HHS or the CDC, Kennedy wouldn’t be able to easily affect vaccine policy. Vaccine recommendations are made by the Advisory Committee on Immunization Practices, which comprises outside medical and public health experts. Georges Benjamin, executive director of the American Public Health Association, says Kennedy could try to stack that advisory committee with people who are sympathetic to his views on vaccination, but those members are chosen through a rigorous nomination process.

“He could certainly change policy that way, but it takes a while and it won't be a secret. There are ways in which the public can push back, including taking a case to court,” he says.

Kennendy could have influence in other ways beyond direct control of a public health agency. Trump could potentially bring Kennedy on as a White House adviser, which wouldn’t require approval by the Senate.

“Without congressional vetting and oversight, there is potential for unchecked impact. RFK's views could shape health policies, raising concerns about misinformation and harm,” Adams says.

Karoline Leavitt, national press secretary for the Trump campaign, told WIRED in an email that if reelected, Trump will establish a “special Presidential Commission of independent minds and will charge them with investigating what is causing the decades-long increase in chronic illnesses.” She did not say whether Kennedy would be chosen for that task force.

Kennedy has also been sizing himself up for another position in a potential Trump cabinet: agriculture secretary. A longtime environmental activist, Kennedy has promised to take on big farms and feedlots, reduce pesticides, and fix what he presents as a food system captured by corporate interests. “When Donald Trump gets me inside,” Kennedy said in a video shot outside the Department of Agriculture headquarters in Washington, DC, “it won’t be that way any more.”

This platform is a continuation of Kennedy’s long history as an antagonist against the agriculture industry. In 2018, Kennedy and a team of attorneys won an initial $289 million settlement against Monsanto, representing a groundskeeper who developed cancer after being soaked with a herbicide made by the agrochemical firm. He also attempted to sue the pig farming company Smithfield because of its production of hog manure, although that case was thrown out by a federal judge.

Kennedy’s past makes him an unlikely candidate for agriculture secretary, according to Daniel Glickman, who served in the role during Bill Clinton’s presidency. “It’s hard for me to imagine, given Trump’s traditional base in the heartlands, that he would pick somebody who was an advocate for breaking up large farms and breaking consolidated agriculture,” says Glickman.

Like top posts at HHS, the USDA secretary position would need to be confirmed by a Senate vote. “I don’t think [Kennedy] is a slam dunk,” says Glickman.

Trump’s pick for USDA chief during his first term was Sonny Perdue, a former governor of Georgia and founder of an agricultural trading company. Most agriculture secretaries either have a background in the industry or politics—two crucial constituencies for the person who will be in charge of a department that employs nearly 100,000 and is made up of 29 agencies, including forestry, conservation, and nutrition programs. “The difference between Sonny Perdue and Robert F. Kennedy, Jr. is like night and day,” says Glickman.

If Kennedy were to be confirmed as agriculture secretary, he might struggle to enact the most radical parts of his program. He is an outspoken critic of pesticides, but the USDA is generally not in charge of regulating those, says Dan Blaustein-Rejto, director of agriculture policy and research at the Breakthrough Institute. Rather, the EPA regulates pesticides with public health uses.

Although he may not be able to directly influence pesticide regulations, Kennedy has said he would try to “weaponize” other agencies against “chemical agriculture” by commissioning scientific research into the effects of pesticides. The USDA Agricultural Research Service has a nearly $2 billion discretionary budget for research into crops, livestocks, nutrition, food safety, and natural resources conservation.

There are other levers that an agriculture secretary could pull, says Blaustein-Rejto. The USDA is investing $3 billion through the partnership for climate-smart commodities—a scheme that’s supposed to make US agriculture more climate-friendly. A USDA chief might be able to put their thumb on their scale by influencing the selection criteria for these kinds of programs. The USDA also oversees the Commodity Credit Corporation (CCC), which has a $5 billion fund that it uses to support farm incomes and conservation programs, and to assist farmers hit by natural disasters. It’s possible that a USDA chief could influence how these CCC funds are distributed by the agency.

Kennedy has also argued that corporate interests have captured the US’s dietary guidelines, and he pledged to remove conflicts of interest from USDA groups that come up with dietary guidelines. US dietary guidelines are developed jointly by the USDA and HHS and are updated every five years, giving the agriculture secretary limited opportunities to influence any recommendations.

“If RFK is in a high-level policy role, I expect to see a lot more talk about ultra-processed foods, but I’m not sure what that would actually entail when it comes to the dietary guidelines,” says Blaustein-Rejto.

The experts WIRED spoke with largely think Kennedy’s more extreme positions will likely be constrained by bureaucracy. But the message that elevating a vocal vaccine skeptic and conspiracy theorist would send remains a serious concern ahead of a potential second Trump administration.

[afeelgoodblog]

The Best News of Last Week

😷 - Mask off, but guard up! Seems like we're out of the tunnel

1. Abandoned dog seen wandering Detroit streets with stuffed toy rescued, now receiving care

An abandoned dog is preparing for a new home after animal rescue groups spent days trying to find her when she was spotted wandering Detroit with a stuffed toy. Nikki's owner recently died, and she was left to wander the streets with her favorite toy. 

As Nikki receives her care, the animal workers are making sure she is ready to head to her foster home. Almost Home is collecting donations to help pay for the treatment and Niki's care. Donate here.

2. New foster care agency matching LGBTQ+ kids with queer carers to become ‘their amazing, wonderful selves’

A new foster care service has been launched to help match LGBTQ+ young people with supportive carers and families in the South East of England. Apex Q, a service from agency Apex Fostering, will help encourage more LGBTQ+ foster carers, provide training and create more placements for queer children.

Apex Fostering, which covers north and east London as well as several southern counties, including Hertfordshire, Essex and Cambridgeshire, launched in 2021 and claims to have already placed more than 60 young people with foster families. 

3. Newquay Zoo celebrates birth of rare 'warty' piglets

A pair of rare piglets has been born at Newquay Zoo in Cornwall. The Visayan warty pigs, named for the three pairs of fleshy "warts" on the boar's face, which protect it while fighting rival pigs, are part of a breeding programme at the zoo.

The species lives in the forests of the Philippines, where there could be as few as 200 animals left.

4. New Alzheimer's drug slows disease by a third

We could be entering the era of Alzheimer's treatments, after the second drug in under a year has been shown to slow the disease. Experts said we were now "on the cusp" of drugs being available, something that had recently seemed "impossible".

The company Eli Lilly has reported its drug - donanemab - slows the pace of Alzheimer's by about a third.

5. Covid global health emergency is over, WHO says

The World Health Organization (WHO) has declared that Covid-19 no longer represents a "global health emergency". The statement represents a major step towards ending the pandemic and comes three years after it first declared its highest level of alert over the virus.

But Dr Tedros Adhanom Ghebreyesus warned that the virus remained a significant threat.

6. Doctors have performed brain surgery on a fetus in one of the first operations of its kind

The baby’s condition, known as vein of Galen malformation, was first noticed during a routine ultrasound scan at 30 weeks of pregnancy. The seven-week-old is one of the first people to have undergone an experimental brain operation while still in the womb. It might have saved her life.

Before she was born, this little girl developed a dangerous condition that led blood to pool in a 14-millimeter-wide pocket in her brain. The condition could have resulted in brain damage, heart problems, and breathing difficulties after birth. It could have been fatal. The baby girl was born healthy. She didn’t need any treatment for the malformation.

7. Lastly, watch this father stork brings a blanket to warm up mother stork

----

That's it for this week :)

This newsletter will always be free. If you liked this post you can support me with a small kofi donation:

Buy me a coffee ❤️

Also don’t forget to reblog. SUBCRIBE HERE for more good news in your inbox

[reasonsforhope]

"Sanofi on Thursday said it’s planning to cut the U.S. price of its most popular insulin drug by 78% and cap monthly out-of-pocket costs at $35 for people who have private insurance starting next year. 

In addition to its widely prescribed Lantus, the French drugmaker will reduce the list price of its short-acting insulin Apidra by 70%. Sanofi already offers a $35 monthly cap on insulin for uninsured diabetes patients.

The company is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts for the lifesaving hormone. 

Eli Lilly and Novo Nordisk made similar sweeping cuts earlier this month after years of political pressure and public outrage over the high costs of diabetes care. The three companies control over 90% of the global insulin market. 

... The change takes effect Jan. 1.

President Joe Biden’s Inflation Reduction Act capped monthly insulin costs for Medicare beneficiaries at $35, but it did not provide protection to diabetes patients who are covered by private insurance.

Sen. Bernie Sanders, a Vermont independent and the chairman of the Senate Health, Education, Labor and Pensions Committee, introduced a bill earlier this month that would cap the list price of insulin at $20 per vial.

Both the president and Sanders on Tuesday directly called on Sanofi to slash its prices after Novo Nordisk announced its own cuts that day.

Roughly 37 million people in the U.S., or 11.3% of the country’s population, have diabetes, according to the Centers for Disease Control and Prevention. Approximately 8.4 million [U.S.] diabetes patients rely on insulin, the American Diabetes Association said."

-via CNBC, 3/16/23

[alldancersaretalented]

Dancers attending P21 Intensive

??

Olivia Elise Victoria Nikolovva

AM Dance

Aurora Monroe

Ale Mancillas Dance Studio

Balbina Cueva

Allegro Performing Arts Academy

Arina Bryzgunova Bella Verbera-Hernandez

Aspirations Dance Company

Lola Nelms

Avanti Dance Company

Hayden Goren Eva Graziano Mia Menji Kaylee Randeniya Rosie Zahoul Sans Blair Tennant

Capitol Dance Company

Malia ?

Center Stage Performing Arts

Tommie Milazzo

Club Dance Studio

Brooklyn Besch Emma Kleve Claire Pistor

Dance Alliance of Camarillo

Shiloh Lark Farrah ?

Dance Dimensions Performic Arts Center

Victoria Safahi Serena Wilcox

DanceDynamicsLV

Lyla Haider

Dance Collective DC

Janelle Liu

Dance Edge Studios

Antonia Zanin

Dance Magic Performic Company

Savannah Lee

Dance Makers of Atlanta

Nola Paulina

Danceology

Ella Bustillos Hudson Hensley Ella Nani Knight Ella Koehnen Soleil Lynch Aria McCrea Cheyenne Ringerman Sydney Swinehart

Dance Republic

Graisyn Clare

Dansé Escuela de Danza

Alexa Ahumada Marielisa Portillo Isabella Trabucco

DC Dance Factory

Pay Lynch

Dolce Dance Studio

Brixtyn Cappo

École de dance Louise

Léonie Macorig

Edge Studios

Sienna ? Aria Giusti

Encore ELite

Leona Zariel

Epic Motion Dance Studio

Maria Sofia Rodríguez Mia Sofia Covarrubias Tinoco

Essence of Dance

Ava Killam Makena Killam Briar ?

Eternal Dance Company

Maddie Kronenberg

Evoke Dance Movement

Emmy Claire

Evolution Dance

Scarlett O'Neil

Evolve Dance Center

Maria Belen Salido

Evolve Dance Centre

Izabella Modarresi

Excel Performing Arts

Emma Sheff

Fusion Dance Omaha

Gigi Murray

Glass House Dance

Eden Cui

Groove Studios WA

Kaiden Koths Abby Mae

Hart Academy of Dance

Lydon Thach

Havilah Dance Company

Caitlyn Marie Malea Jade Moore

Inferno Dance Co

Maizie Smith

Instyle Dance Company

Jacilynn Mar

Janet Dunstans Dance Academy

Adeline Glenn

K2 Studios

Neriah Karmann Lennon Reign Jessica Sutton

Larkin Dance Studio

Matinly Conrad Palmer Petier

Legacy Dance Productions

Sophie Boonstra Paisley Clarke

Legacy Studio of Performing Arts

Brynne Smith

McKinley School of Dance

Teodora Narancic

Murrieta Dance Project

Khloe Cabrera Gracie Gilroy

N10 Dance Studio

Claire Avonne Kingston Madison Ng

No Limits Dance Academy

Ayanna Voulgaris

Nor Cal Dance Arts

Aria Davi Aubrey Paz Olyvia Reza

North Calgary Dance Centre

Ellie Blakley Georgia Blakley

OCPAA

Libby Haye

Onstage Dance Center - Los Alamitos

Adalyn Nicole

Pave San Diego

Eleanor Bullock Aryanna La Fontaine Cooper

Pave School of the Arts

Sofia Cuevas Stella Fisk Livi Matson

Perception Dance

Mabel James

Project 21

Ellie Anbarden Olivia Armstrong Lilly Barajas Sienna Carlston Kami Couch Katie Couch Kenzie Couch Airi Dela Cruz Stella Eberts Gracyn French Regan Gerena Richie Granese Mady Kim Brooklyn Ladia Leilani Lawlor Chloe Mirabel Savanna Musman Madelyn Nasu Avery Reyes Berkeley Scifres Bristyn Scifres Sara Von Rotz Leighton Werner

Project 520 Dance Studio

Adelynn ? Karli Heim Sasha Muratalieva

Queen City Dance

Annabel Speck

Seattle Storm Dance Troupe

Claire Clark

Shooting Stars Dance Studio

Karsyn Hernandez Malani Maliya

Stars Dance Studio

Hannah Burak Catherine Clayton Fabiana Pierleoni Elie Rabin

Starstruck Performing Arts Center KS

Kinley Winn

Steps Dance Center

Emmie Pitt

Studio Fusion

Harley Gross Juliet Anne Wydo

The Collaborative

Addison Cullather

The Company Space

Piper Perusse Stella Marcordes Vivian Marcordes

TheCREW

Isabella Tamayo

The Dance Collective DC

Eva Rogachevsky Quincy Thomas

The Dance Collective MD

Lyla Urban

The Dance Company of Los Gatos

Scarlett Blu Chloe Rose

The Vision Dance Alliance

Emily Polis

Utah Ballet Festival

Ruby Taylor

West Coast Dance Complex

Mila Barnett

Xtreme Dance Studio

Jocelyn Longroy

YYC Dance Project

Kinsley Oykhman

[adrie-75014]

The Aurikno crime family really went:

[Image Description: a screenshot of a tweet, from a verified account posing as the pharmaceutical company Eli Lilly saying: “We are excited to announce insulin is free now." The account is not the official Eli Lilly company account, but is made to look very legitimate]